Poseida Therapeutics, Inc.

Today, we released new #clinical data for our lead allogeneic CAR-T program at #IMS24. These #data continue to validate the potential positive efficacy and safety of our platforms and technologies for the treatment of #myeloma. Read the press release: https://lnkd.in/e88MrKJN We will hold a #webcast conference call tomorrow, Saturday September 28 at 10am PT | 1pm ET to discuss the results. Details here: https://lnkd.in/euY5mmFc #CapacitytoCure #celltherapy International Myeloma Society

Today we announced new preclinical #data, to be presented at the #ACAAI24 Annual Scientific Meeting in Boston, supporting the potential of P-KLKB1-101 to provide a differentiated treatment option for #hereditaryangioedema with encouraging early tolerability, safety and efficacy results.    All details here: https://lnkd.in/emHEANen   #CapacitytoCure #geneticmedicines #geneediting #HAE

Partnerships remain a key driver of the progress being made in #CellAndGeneTherapy to deliver breakthrough oncology treatments. Our EVP, Head of Corporate Strategy, Peter Sandor and Poseida Therapeutics’ CEO, Kristin Yarema, Ph.D., sat down with In Vivo to discuss how aligning on a shared vision early in the dealmaking process, combining expertise, and empowering teams to act quickly can accelerate progress for patients. At Astellas, we actively seek partnerships with ambitious companies like Poseida Therapeutics who share our deep commitment to science and patient care. To learn more on how we are working together to advance allogeneic CAR-T cell therapies to potentially transform the lives of cancer patients, read on here: https://lnkd.in/dUh8bcH3 *You may need to register to read the article. #ScienceFirstForPatients #ChangingTomorrow

We are thrilled to announce that our #celltherapy partner Roche has chosen to expand our collaboration with the nomination of a new #allogeneic dual CAR-T candidate that targets antigens expressed in hematologic malignancies, including #multiplemyeloma. This choice reaffirms the strength of our partnership and our shared belief that products rich in stem cell memory T cells are key to developing successful CAR-Ts.    More on this latest milestone: https://lnkd.in/e8VZwgJY   #CapacitytoCure

Did you know that 1 in 8 women in the U.S. will face a breast cancer diagnosis in her lifetime? It’s crucial that we stand ready to support them. This #BreastCancerAwareness Month, we reaffirm our commitment to developing innovative therapies with the #capacitytocure. Let’s keep the patients and families we serve at the forefront of our mission. #celltherapy #geneticmedicines

We are excited to announce that team members from Poseida will be presenting a poster demonstrating the power of our non-viral #allogeneic technology to engineer CARs and TCRs simultaneously into T cells at #SITC24 in Houston. Presentation info. available now: https://lnkd.in/efM9i6Py #CapacitytoCure #celltherapy Society for Immunotherapy of Cancer (SITC)

Want firsthand insight into our clinical trial for P-BCMA-ALLO1? Read this article from AJMC - The American Journal of Managed Care for a Q&A with Bhagirathbhai Dholaria, M.D., on our investigational CAR-T therapy in #multiplemyeloma and potential benefits for patients: https://lnkd.in/eyeMdHcH  #CapacitytoCure #celltherapy

We are excited to share that our CEO, Kristin Yarema, Ph.D., has been recognized on the PharmaVoice 100 list as a pioneer in cell and gene therapy. More on her #recognition, her #career to date, and the full list of inspiring industry leaders out now: https://lnkd.in/e8nV6kYA   #CapacitytoCure #celltherapy #geneticmedicines #PharmaVoice100 #PV100

#Myeloma luminary Tom Martin, M.D., shares his thoughts and impressions on our recently announced Phase1b clinical #data for P-BCMA-ALLO1. Be sure to tune in for more on his reflections on the overall response rate in a refractory patient population. Full conference call webcast here: https://lnkd.in/eSD9W4kB #CapacitytoCure #celltherapy

Be sure to join our CEO, Kristin Yarema, Ph.D., and Astellas’ CSO, Yoshitsugu Shitaka, for an exciting fireside chat tomorrow on all things oncology, CAR-T, and our ongoing collaboration to develop novel allogeneic cell therapies leveraging Astellas’ convertibleCAR technology in unison with Poseida’s non-viral approach at #CGMesa24 in Phoenix. We look forward to seeing you there in person, if attending. https://lnkd.in/eiUpMy4 #CapacitytoCure #celltherapy #geneticmedicines Alliance for Regenerative Medicine Astellas Pharma